PURPOSE: Given the implications for clinical care and prevention in identifying a @entity6069 mutation, the objective of this study was to determine current @entity5345 /2 testing practices in @entity43 and to identify future directions. METHODS: Two parallel complementary web-based surveys were sent by email to representatives of @entity5 InterGroup (GCIG) and to referral centers in countries with and without GCIG membership. Questions posed addressed indications of @entity5345 /2 testing for @entity43 ; the implication of genetic counseling; and prevention strategies employed. RESULTS: Among the GCIG, 22 collaborative groups from 19 countries answered the survey. For the complementary survey, 22 referral centers replied. Findings show criteria to offer germline @entity5345 /2 testing are mixed; 55% of GCIG members based testing decisions on histology and, among all respondents the main testing criterion remains family history. Typically, genetic counseling is scheduled prior to the genetic testing; however, if negative, results may not be communicated by the genetic counselor. Time between testing and communicating results varies widely between the groups. Lastly, recommendations to relatives regarding risk reduction surgery are inconsistent. CONCLUSION: Our study highlights the need for collaborative efforts to devise international guidelines around @entity6069 testing in @entity43 to ensure consistent @entity6069 screening practices are adopted. Clinical practice is evolving rapidly and as @entity6069 testing is expected to become more widespread, new approaches are required. Coordinating @entity5345 /2 testing practices is crucial in terms of care for the @entity1 diagnosed with @entity43 but also towards @entity5 prevention for affected family members.

Germline XXXX testing practices in @entity43 : Current state and opportunities for new directions.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity5345 :: ('672', 'Gene') :: ['BRCA1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Gynecologic Cancer'] @entity6069 :: ('672;675', 'Gene') :: ['BRCA1/2']
@entity6069 :: (672;675,Gene) :: ['BRCA1/2']
